The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2025 | Emerging T-cell engagers in small cell lung cancer
Anna Minchom, MD, BCh, MB, MRCP, The Royal Marsden Hospital, London, UK, discusses emerging therapeutics in small cell lung cancer, particularly T-cell engagers (BiTes) like tarlatamab. This novel drug targets DLL3 and CD3, activating T-cells to attack cancer cells, with promising efficacy data. However, its clinical use presents challenges, particularly the management of cytokine release syndrome, which can lead to cardiac and respiratory instability requiring specialized care and extended inpatient monitoring. This interview took place at the BTOG 2025 congress in Belfast, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
